89bio logo
89bio ETNB
report update icon

Quarterly report 2025-Q2
added 05-23-2026

89bio Balance Sheet 2024-2011 | ETNB

Brief balance sheet overview of 89bio

The review uses the five latest available annual reports between 2020 and 2024.

Assets rose from $211.1 million to $478.7 million, a gain of +126.8%, while CAGR was about 22.7%. The balance sheet expanded rapidly.

Asset growth of +126.8% came with a +860.1% rise in liabilities. Financial leverage became more prominent.

The equity-to-assets ratio is 83.7%, compared with 96.2% five periods ago. The balance sheet has a substantial internal cushion.

Negative net debt of -$89.6 million means cash holdings are larger than debt obligations.

The cash reserve occupies 26.3% of the balance sheet, previously 46.5%. It is one marker of short-term resilience.

The balance sheet carries negative retained earnings of -$824.5 million. The figure may result from accumulated losses or an active capital return policy.

Overall assessment

89bio's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.

Annual Balance Sheet 89bio

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-89.6 M -291 M -34.9 M -33 M -98.2 M -93.3 M -11.2 M - - - - - - -

Long Term Debt

35.7 M 24.8 M 20.2 M 16.9 M - - - - - - - - - -

Long Term Debt Current

727 K 496 K 168 K 2.5 M - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 23.1 M - - - - - - -

Total Current Liabilities

36.1 M 29.6 M 24.6 M 19.5 M 8.11 M 5.61 M - - - - - - - -

Total Liabilities

77.9 M 60 M 45 M 36.5 M 8.11 M 5.61 M 27.4 M - - - - - - -

Retained Earnings

-825 M -457 M -315 M -213 M -123 M -73.6 M -16.2 M - - - - - - -

Total Assets

479 M 596 M 197 M 162 M 211 M 95.6 M 11.4 M - - - - - - -

Cash and Cash Equivalents

126 M 316 M 55.3 M 52.4 M 98.2 M 93.3 M 11.3 M - - - - - - -

Book Value

401 M 536 M 152 M 126 M 203 M 89.9 M -16.1 M - - - - - - -

Total Shareholders Equity

401 M 536 M 152 M 126 M 203 M 89.9 M -16.1 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet 89bio

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

36.2 M 35.9 M 35.7 M 35.5 M 20.4 M 23.1 M 24.8 M 24.6 M 24.5 M - 20.2 M 13 M 12 M 14.5 M 16.9 M 1.44 M 1.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

81.8 M 79.6 M 77.9 M 80.2 M 67.2 M 66.8 M 60 M 49.9 M 50.5 M - 45 M 48 M 67.4 M 33 M 36.5 M 21.3 M 9.01 M - 8.11 M 8.11 M 8.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.01 B -896 M -825 M -706 M -557 M -509 M -457 M -417 M -382 M - -315 M -291 M -264 M -239 M -213 M -187 M -159 M -138 M -123 M -123 M -123 M -123 M -73.6 M -73.6 M -73.6 M -73.6 M -16.2 M -16.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

603 M 685 M 479 M 458 M 582 M 577 M 596 M 460 M 493 M - 197 M 201 M 148 M 136 M 162 M 168 M 182 M 199 M 211 M 211 M 211 M 211 M 95.6 M 95.6 M 95.6 M 95.6 M 11.4 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

129 M 315 M 126 M 91.4 M 212 M 218 M 316 M 252 M 245 M 351 M 55.3 M 72.4 M 60.6 M 54.9 M 52.4 M 39.7 M 35.7 M 68 M 98.2 M 98.2 M 98.2 M 98.2 M 93.3 M 93.3 M 93.3 M 93.3 M 11.2 M 11.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

522 M 605 M 401 M 378 M 515 M 511 M 536 M 410 M 442 M - 152 M 153 M 80.2 M 103 M 126 M 147 M 173 M 199 M 203 M 203 M 203 M 211 M 95.6 M 95.6 M 95.6 M 95.6 M 11.4 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

522 M 605 M 401 M 378 M 515 M 511 M 536 M 410 M 442 M 446 M 152 M 153 M 80.2 M 103 M 126 M 147 M 173 M 190 M 203 M 203 M 203 M 203 M 89.9 M 89.9 M 89.9 M 89.9 M -16.1 M -16.1 M -7.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of 89bio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.6 5.56 % $ 6.41 B israelIsrael
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 64.67 0.11 % $ 12.4 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.85 0.12 % $ 319 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.78 1.13 % $ 3.03 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 34.07 0.17 % $ 382 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 5.6 2.06 % $ 3.74 M usaUSA
Codexis Codexis
CDXS
$ 1.59 0.3 % $ 139 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.1 1.25 % $ 303 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 199.02 0.31 % $ 9.9 B usaUSA
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.28 0.1 % $ 1.62 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aytu BioScience Aytu BioScience
AYTU
$ 2.25 0.45 % $ 14.1 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada